Literature DB >> 33596364

Osimertinib in EGFR-Mutated Lung Cancer.

Wenhua Liang1, Ran Zhong1, Jianxing He1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33596364     DOI: 10.1056/NEJMc2033951

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of anlotinib as a third-line treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.

Authors:  Bowen Zha; Yuxin Zhang; Runzi Yang; Muladili Kamili
Journal:  Oncol Lett       Date:  2022-05-27       Impact factor: 3.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.